LYEL vs FC Comparison

Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.